Status:
COMPLETED
Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
This study was designed to look at safety aspects and effects of intranasal doses of GW784568X on allergic rhinitis symptoms to develop this drug for its use in people who suffer with allergic rhiniti...
Detailed Description
A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X (100mcg, 200mcg and 400mcg od), fluticasone propionate (200mcg od) and placebo (b...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy with exception of seasonal rhinitis. May also have mild asthma.
- Weight greater than or equal to 50kg
- Non-smoker for at least 12 months
- Exclusion criteria:
- History of frequent nosebleeds
- Have participated in another trial in the last 30 days.
- Have donated blood in the previous 3 months
- Have used prescription or non prescription drugs within last 7 days
- Have history of alcohol/drug abuse within last 12 months
- Have positive Hepatitis B or C test within 3 months of screening
- Subject tested positive for HIV
Exclusion
Key Trial Info
Start Date :
September 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 16 2007
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00404586
Start Date
September 11 2006
End Date
January 16 2007
Last Update
September 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Hanover, Lower Saxony, Germany, 30625